On this basis, we investigated the role of NANOG protein expression as an early cancer risk biomarker in oral potentially malignant disorders (OPMD), and the impact on prognosis and disease outcomes in OSCC patients. The gene discussed is NANOG; the disease is oculopharyngeal muscular dystrophy.